News

Thu, 2014-04-03
Dyax Receives FDA Approval to Expand Use of Kalbitor(R)

Dyax Corp. today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute HAE attacks, to include patients 12 years of age and older.

With this approval, KALBITOR is the first and only subcutaneous therapy available to treat acute attacks of HAE in patients 12 years of age and older. KALBITOR is also the only therapy that is not purified from human plasma that has been approved to treat this patient group.

Thu, 2014-03-27
From the Shire 2013 Annual Report

From the Shire 2013 Annual Report published today:

Fri, 2014-03-14
Dyax Announces Pricing of $74 Million Public Offering of Common Stock

Dyax Corp. today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $9.25 per share. The gross proceeds to Dyax from this offering are expected to be $74 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Dyax.

Tue, 2014-03-04
Patient Satisfaction and Convenience Increased with Current HAE Treatment Options, According to Study Findings

Findings announced by CSL Behring today show that current HAE treatment options, such as C1 Esterase Inhibitor (C1-INH) concentrate, are allowing for greater patient satisfaction, higher rates of home treatment and a decrease in the number of hospitalizations and visits to the emergency room.

Until recently, only limited therapeutic options were available for patients in the U.S. with the condition. Today, HAE patients can choose from multiple options to address their condition.

Mon, 2014-03-03
BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results

BioCryst Pharmaceuticals, Inc. announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161, together with details of the Company's plasma kallikrein inhibition assay. BCX4161 is currently being evaluated in a Phase 2 clinical trial, OPuS-1, as a potential treatment for the prevention of HAE attacks.

Teaser 4, 2nd row left, in news section

United We Stand Strong!

HAEi cares about you. We encourage patients to get organized - because "United We Stand Strong".

HAE International - Thumb 7HAE International - Thumb 7Become a National Member Organization (NMO). We are here to help you in founding a National Member Organization. Follow our step-by-step model. It doesn't have to be a difficult task creating the best foundation for patients in your country. Contact us for more information here


HAE International - Thumb 4HAE International - Thumb 4

Starting a National Patient Group (NPG). If you are interested in doing more around HAE - but don't feel that starting a full NMO is the right option here and now. You should maybe consider becoming a contact patient (NPG) for your country. Contact us here

Both NMO's and NPG's enjoy free membership of HAEi. Also we can help you host your country specific website under the global umbrella of HAEi.

Events

Fri, 2014-05-16 (All day)

2014 hae day :-)

On 16 May 2014 patient organizations throughout the globe will hold events, meetings, and fundraisers to support the global awareness day hae day :-)

..continue
Thu, 2014-05-15 12:00 - Sun, 2014-05-18 12:00

2014 HAE Global Conference

Venue: Hyatt Regency Reston, 1800 Presidents St., Reston, VA 20190, United States of America
Language: English

HAEi - International Patient Organization for C1 Inhibitor Deficiencies cordially invites you to attend the 2014 HAE Global Conference which will take place in Washington DC, 15 - 18 May 2014.

Registration for the conference is now open! Registration will take place on a first come, first serve basis – and since we again offer some extremely attractive registration rates and conditions, please do not wait too long registering for this exciting conference.

Please register here

..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


See the video from the 2012 HAE Global Conference in Copenhagen

Click here


HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014


www.haeday.org